{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:33:56Z","timestamp":1790746436705,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12032-018-1187-3","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:17:18Z","timestamp":1533255438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid malignancies and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1187_CR2","first-page":"2870296","volume":"2014","author":"J Nangalia","year":"2014","unstructured":"Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2014;2014:2870296.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1187_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/17474086.2017.1380515","volume":"10","author":"F Schischlik","year":"2017","unstructured":"Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms\u2014their significance and clinical use. Expert Rev Hematol. 2017;10:961\u201373.","journal-title":"Expert Rev Hematol"},{"key":"1187_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584\u201396.","journal-title":"Cancer Cell"},{"key":"1187_CR5","first-page":"1834","volume":"4","author":"J Li","year":"2011","unstructured":"Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4:1834\u20139.","journal-title":"Dis Model Mech"},{"key":"1187_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1307\u201316.","journal-title":"Blood"},{"key":"1187_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2008-10-183558","volume":"115","author":"C Pecquet","year":"2010","unstructured":"Pecquet C, Staerk J, Chaligne R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115:1037\u201348.","journal-title":"Blood"},{"key":"1187_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM. The JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Am J Hematol. 2011;86:668\u201376.","journal-title":"Am J Hematol"},{"key":"1187_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti W, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515E> L\/K mutation in essential thrombocythemia. Blood. 2008;112:844\u20137.","journal-title":"Blood"},{"key":"1187_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"1187_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"1187_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"1187_CR14","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28:1804\u201310.","journal-title":"Leukemia"},{"key":"1187_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients with Primary Myelofibrosis. J Clin Oncol. 2018;36:310\u20138.","journal-title":"J Clin Oncol"},{"key":"1187_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative Neoplasms. A Contemporary Review. JAMA Oncol. 2015;1:97\u2013105.","journal-title":"JAMA Oncol"},{"key":"1187_CR17","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical Characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood"},{"key":"1187_CR18","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","volume":"131","author":"F Passamonti","year":"2018","unstructured":"Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPNs 7 years after approval. Blood. 2018;131:2426\u201335.","journal-title":"Blood"},{"key":"1187_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10:156.","journal-title":"J Hematol Oncol"},{"key":"1187_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/leu.2016.323","volume":"31","author":"CV Harrison","year":"2017","unstructured":"Harrison CV, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase of 3 study of ruxolitinib vs best available therapy for myelofibrosis: 5-year final study results. Leukemia. 2017;31:775.","journal-title":"Leukemia"},{"key":"1187_CR21","doi-asserted-by":"publisher","first-page":"670580","DOI":"10.1155\/2015\/670580","volume":"2015","author":"J Mondet","year":"2015","unstructured":"Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in Philadelphia-negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediators Inflamm. 2015;2015:670580.","journal-title":"Mediators Inflamm"},{"key":"1187_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139\u201345.","journal-title":"Haematologica"},{"key":"1187_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vaichenker","year":"2017","unstructured":"Vaichenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"1187_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018;11:42.","journal-title":"J Hematol Oncol"},{"key":"1187_CR25","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","volume":"98","author":"BS Wilkins","year":"2013","unstructured":"Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patients receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98:1872\u20136.","journal-title":"Haematologica"},{"key":"1187_CR26","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00277-014-2096-y","volume":"93","author":"M Molica","year":"2014","unstructured":"Molica M, Serrao A, Saracino R, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve. Ann Hematol. 2014;93:1951\u20132.","journal-title":"Ann Hematol"},{"key":"1187_CR27","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood.V124.21.1836.1836","volume":"124","author":"HK Al-Ali","year":"2014","unstructured":"Al-Ali HK, Hubert K, Lange T, et al. Complete clinical, histopathologic and molecular remission of primary myelofibrosis with long-term treatment with the JAK1\/2 inhibitor ruxolitinib. Blood. 2014;124:1836.","journal-title":"Blood"},{"key":"1187_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizatto A. Ruxolitinib-associated infections: a systemic review and meta-analysis. Am J Hematol. 2018;93:339\u201347.","journal-title":"Am J Hematol"},{"key":"1187_CR29","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126:1551\u20134.","journal-title":"Blood"},{"key":"1187_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","volume":"123","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123:2157\u201360.","journal-title":"Blood"},{"key":"1187_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clml.2013.09.006","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis\u2014an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013;13:638\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1187_CR32","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","volume":"101","author":"V Gupta","year":"2016","unstructured":"Gupta V, Harrison C, Hexner EU, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101:e482\u20134.","journal-title":"Haematologica"},{"key":"1187_CR33","first-page":"CD010298","volume":"10","author":"AJ Marti-Carvajal","year":"2015","unstructured":"Marti-Carvajal AJ, Anand V, Sola I. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015;10:CD010298.","journal-title":"Cochrane Database Syst Rev"},{"key":"1187_CR34","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, KIladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844\u201350.","journal-title":"J Clin Oncol"},{"key":"1187_CR35","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib vesrus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY-2): a randomized, open-label, phase 3 trial. Lancet Haematol. 2018;5:e73\u201381.","journal-title":"Lancet Haematol"},{"key":"1187_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8:29.","journal-title":"Blood Cancer J"},{"key":"1187_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","volume":"8","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016;8:137.","journal-title":"J Hematol Oncol"},{"key":"1187_CR38","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomized, phase 3 trial. Lancet Haematol. 2017;4:e225\u201336.","journal-title":"Lancet Haematol"},{"key":"1187_CR39","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652\u20139.","journal-title":"JAMA Oncol"},{"key":"1187_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3309-6","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Virtgaym E, Stal M, et al. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol. 2018. https:\/\/doi.org\/10.1007\/s00277-018-3309-6 .","journal-title":"Ann Hematol"},{"key":"1187_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes J, et al. Safety and efficacy of Fedratinib in Patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1187_CR42","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase2, multicenter study. Lancet Haematol. 2017;4:e317\u201324.","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"1187_CR43","first-page":"4197","volume":"130","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Mesa RA, Jamieson C, et al. Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib [abstract]. Blood. 2017;130(suppl 1):4197.","journal-title":"Blood"},{"key":"1187_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. N Eng J Med. 2015;372:426\u201335.","journal-title":"N Eng J Med"},{"key":"1187_CR45","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","volume":"96","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96:1113\u201320.","journal-title":"Ann Hematol"},{"issue":"suppl. 1","key":"1187_CR46","first-page":"32","volume":"130","author":"JJ Kiladjian","year":"2017","unstructured":"Kiladjian JJ, Verstovsek S, Griesshammer M, et al. Results from the 208-week (4 year) follow-up of the RESPONSE Trial, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of polycythemia vera [abstract]. Blood. 2017;130(suppl. 1):322.","journal-title":"Blood"},{"key":"1187_CR47","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","volume":"130","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130:1889\u201397.","journal-title":"Blood"},{"key":"1187_CR48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","volume":"130","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant to hydroxyurea: a long-term phase 2 study results. Blood. 2017;130:1768\u201371.","journal-title":"Blood"},{"key":"1187_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.leukres.2017.05.002","volume":"60","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Courby S, Griesshammer M, et al. A phase 2 study of momelotinib, a poten JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017;60:11\u20137.","journal-title":"Leuk Res"},{"key":"1187_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors. Biol Blood Marrow Transplant. 2016;22:432\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1187_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/ejh","author":"SSA Kadir","year":"2018","unstructured":"Kadir SSA, Christopoiet S, Gerald MW, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018. https:\/\/doi.org\/10.1111\/ejh .","journal-title":"Eur J Haematol"},{"key":"1187_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.023","author":"N Kroger","year":"2018","unstructured":"Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2018. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.023 .","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1187-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1187-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1187-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T15:40:53Z","timestamp":1571672453000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1187-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1187-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"28 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author disclosed no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"119"}}